Features of liver function in pediatric patients infected with Delta variant versus Omicron variant of severe acute respiratory syndrome coronavirus 2

Ye ZHAO; Jialong GUAN; Yuzhen MAI; Haohui DENG

doi:10.3969/j.issn.1001-5256.2022.09.023

Volume 38 Issue 9

Sep. 2022

Turn off MathJax

Article Contents

Abstract

References

Article Navigation > Journal of Clinical Hepatology > 2022 > 38(9): 2073-2077

PDF( 1947 KB)

Features of liver function in pediatric patients infected with Delta variant versus Omicron variant of severe acute respiratory syndrome coronavirus 2

DOI: 10.3969/j.issn.1001-5256.2022.09.023

No. 20 Isolation Ward, Guangzhou Eighth People's Hospital, Guangzhou Medical University, Guangzhou 510060, China

Research funding:

Medical Scientific Research Foundation of Guangdong Province (B2021302);

Foundation of Key Medical Disciplines in Guangzhou Gity(2021-2023)-Viral Infectious Diseases (202208XK0002)

More Information

Corresponding author: DENG Haohui, gz8hdhh@126.com(ORCID: 0000-0001-5948-9101)
Received Date: 2022-05-13
Accepted Date: 2022-06-15
Published Date: 2022-09-20

Abstract

Abstract

Objective To summarize and analyze the features of liver function in pediatric patients infected with Delta variant versus Omicron variant of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Methods In this study, an analysis was performed for the liver function test results of the locally transmitted or imported pediatric patients with SARS-CoV-2 infection during isolation who were admitted to Guangzhou Eighth People's Hospital, Guangzhou Medical University, since May 21, 2021, and the clinical data and the constituent ratio of liver injury were compared between the pediatric patients infected with Delta variant and those infected with Omicron variant. The independent samples t-test or the Mann-Whitney U test was used for comparison of continuous data between two groups, and the chi-square test or the Fisher's exact test was used for comparison of categorical data between two groups. Results A total of 85 pediatric patients infected with SARS-CoV-2 were enrolled, among whom there were 32 (37.6%) pediatric patients infected with Delta variant and 53 (62.4%) pediatric patients infected with Omicron variant, and there were no significant differences between the two groups in age, sex, body height, body weight, and comorbidities (all P > 0.05). There were no significant differences between the two groups in alanine aminotransferase (ALT), aspartate aminotransferase (AST), alkaline phosphatase (ALP), gamma-glutamyl transpeptidase, total bilirubin, albumin, and cholinesterase (all P > 0.05), and the pediatric patients infected with Omicron variant had a significantly higher level of total bile acid (TBA) than those infected with Delta variant (Z=-2.336, P=0.020). However, the median values of TBA were within the normal range and the ratios of abnormal TBA were no significant difference between the two groups (P > 0.05). Among the 85 pediatric patients, 10 (11.8%) had a mild increase in liver function parameters, among whom 7 had an increase in TBA, 1 had an increase in ALT, 1 had increases in ALT and AST, and 1 had an increase in ALP. The analysis of liver injury in the pediatric patients infected with Delta variant or Omicron variant showed that there was no significant difference in the constituent ratio of liver injury caused by the two variants (6.3% vs 15.1%, χ²=0.691, P=0.406). Conclusion Mild liver injury is observed in pediatric patients infected with Delta and Omicron variants of SARS-CoV-2, but further studies are needed to evaluate the long-term influence of such infection on liver function.
- SARS-CoV-2,
- Liver Injury,
- Child

FullText(HTML)

References(17)

References

[1]	MARSH K, TAYLER R, POLLOCK L, et al. Investigation into cases of hepatitis of unknown aetiology among young children, Scotland, 1 January 2022 to 12 April 2022[J]. Euro Surveill, 2022, 27(15): 2200318. DOI: 10.2807/1560-7917.ES.2022.27.15.2200318.
[2]	National Health Commission of the People's Republic of China. Diagnosis and treatment plan for COVID-19 (trial version 9)[J]. Inter J Epidemiol Infect Dis, 2022, 49(2): 73-80. DOI: 10.3760/cma.j.cn331340-20220325-00065. 中国国家卫生健康委员会. 新型冠状病毒肺炎诊疗方案(试行第九版)[J]. 国际流行病学传染病学杂志, 2022, 49(2): 73-80. DOI: 10.3760/cma.j.cn331340-20220325-00065.
[3]	American College of Clinical Pharmacy. Reference values for common laboratory tests[EB/OL]. https://www.accp.com/docs/sap/Lab_values_Table_PedSAP.pdf.
[4]	World Health Organization. Disease Outbreak News; Acute hepatitis of unknown aetiology-the United Kingdom of Great Britain and Northern Ireland (15 April 2022)[EB/OL]. https://www.who.int/emergencies/disease-outbreak-news/item/2022-DON368.
[5]	MA K, YANG ZY, CHEN T, et al. Pay close attention to the current characteristics and development trend of severe acute hepatitis with unknown etiology in children worldwide[J]. Natl Med J China, 2022, 102(20): 1429-1432. DOI: 10.3760/cma.j.cn112137-20220505-00986. 马科, 杨中原, 陈韬, 等. 高度关注当前全球多国不明原因儿童严重急性肝炎的特征及发展动向[J]. 中华医学杂志, 2022, 102(20): 1429-1432. DOI: 10.3760/cma.j.cn112137-20220505-00986.
[6]	RONAN BA, AGRWAL N, CAREY EJ, et al. Fulminant hepatitis due to human adenovirus[J]. Infection, 2014, 42(1): 105-111. DOI: 10.1007/s15010-013-0527-7.
[7]	KAWASHIMA N, MURAMATSU H, OKUNO Y, et al. Fulminant adenovirus hepatitis after hematopoietic stem cell transplant: Retrospective real-time PCR analysis for adenovirus DNA in two cases[J]. J Infect Chemother, 2015, 21(12): 857-863. DOI: 10.1016/j.jiac.2015.08.018.
[8]	BOETTLER T, CSERNALABICS B, SALIÉ H, et al. SARS-CoV-2 vaccination can elicit a CD8 T-cell dominant hepatitis[J]. J Hepatol, 2022. DOI: 10.1016/j.jhep.2022.03.040.[Online ahead of print]
[9]	ZHU Z, MAO NY, ZHANG Y, et al. Consideration on the emerging of severe acute hepatitis cases with of unknown etiology in children worldwide[J]. Chin J Prevent Med, 2022, 56(6): 679-681. DOI: 10.3760/cma.j.cn112150-20220427-00423. 朱贞, 毛乃颖, 张燕, 等. 对当前全球部分国家出现的不明原因儿童急性严重肝炎病例的思考[J]. 中华预防医学杂志, 2022, 56(6): 679-681. DOI: 10.3760/cma.j.cn112150-20220427-00423.
[10]	LIN HW, LEI Y, CHEN BB, et al. Clinical features of patients with severe acute respiratory syndrome coronavirus 2 Delta variant infection and abnormal liver function in Guangdong Province, China[J]. J Clin Hepatol, 2022, 38(3): 582-586. DOI: 10.3969/j.issn.1001-5256.2022.03.017. 林浩炜, 雷燕, 陈彬彬, 等. 广东地区新型冠状病毒Delta变异株感染并发肝功能异常患者的临床特征分析[J]. 临床肝胆病杂志, 2022, 38(3): 582-586. DOI: 10.3969/j.issn.1001-5256.2022.03.017.
[11]	EKPANYAPONG S, BUNCHORNTAVAKUL C, REDDY KR. COVID-19 and the liver: Lessons learnt from the EAST and the WEST, a year later[J]. J Viral Hepat, 2022, 29(1): 4-20. DOI: 10.1111/jvh.13590.
[12]	HUANG YK, LI YJ, LI B, et al. Dysregulated liver function in SARS-CoV-2 infection: Current understanding and perspectives[J]. World J Gastroenterol, 2021, 27(27): 4358-4370. DOI: 10.3748/wjg.v27.i27.4358.
[13]	VIANA R, MOYO S, AMOAKO DG, et al. Rapid epidemic expansion of the SARS-CoV-2 Omicron variant in southern Africa[J]. Nature, 2022, 603(7902): 679-686. DOI: 10.1038/s41586-022-04411-y.
[14]	ADAM D. What scientists know about new, fast-spreading coronavirus variants[J]. Nature, 2021, 594(7861): 19-20. DOI: 10.1038/d41586-021-01390-4.
[15]	DENG H, LIN H, MAI Y, et al. Clinical features and predictive factors related to liver injury in SARS-CoV-2 Delta and Omicron variant-infected patients[J]. Eur J Gastroenterol Hepatol, 2022. DOI: 10.1097/MEG.0000000000002381.[Online ahead of print]
[16]	CHAI XQ, HU LF, ZHANG Y, et al. Specific ACE2 expression in cholangiocytes may cause liver damage after 2019-nCoV infection[J]. bioRxiv, 2020. DOI: 10.1101/2020.02.03.931766.[Online ahead of print]
[17]	BRODIN P, ARDITI M. Severe acute hepatitis in children: investigate SARS-CoV-2 superantigens[J]. Lancet Gastroenterol Hepatol, 2022, 7(7): 594-595. DOI: 10.1016/S2468-1253(22)00166-2.

Relative Articles

[1]	Zhang ChunYu, Liu ZuoJin. Surgical treatment of cirrhotic portal hypertension: Current status and research advances[J]. Journal of Clinical Hepatology, 2020, 36(2): 417-420. doi: 10.3969/j.issn.1001-5256.2020.02.040
[2]	Yao Xin, Zhou Hao, Tang ShanHong, Huang Shan, Chen XueLing, Qin JianPing. Effect of intraoperative Viatorr stent implantation for shunting of blood flow in the left or right branch of the portal vein and its effect on clinical outcome in patients with cirrhotic portal hypertension undergoing transjugular intrahepatic portosystemic shunt[J]. Journal of Clinical Hepatology, 2020, 36(9): 1970-1974. doi: 10.3969/j.issn.1001-5256.2020.09.012
[3]	Mu XueChun, Wang Yu, Ma Hong. Noninvasive assessment of cirrhotic portal hypertension[J]. Journal of Clinical Hepatology, 2019, 35(12): 2796-2799. doi: 10.3969/j.issn.1001-5256.2019.12.033
[4]	Xiao Peng, Zhang YaNan, Ba TaoTao, Ding MengMeng, Gao YanHang. Application of serological markers in noninvasive assessment of cirrhotic portal hypertension[J]. Journal of Clinical Hepatology, 2019, 35(9): 2075-2078. doi: 10.3969/j.issn.1001-5256.2019.09.042
[5]	Xu Hui, Zhang Feng, Zhang Ming, Zhu GeYuZheng. Effect of propranolol on hemodynamics and its clinical significance in patients with portal hypertension[J]. Journal of Clinical Hepatology, 2019, 35(4): 801-807. doi: 10.3969/j.issn.1001-5256.2019.04.019
[6]	He Bo, Zhang ChunQing. Mechanism and current status of carvedilol in treatment of cirrhotic portal hypertension[J]. Journal of Clinical Hepatology, 2019, 35(2): 399-401. doi: 10.3969/j.issn.1001-5256.2019.02.036
[7]	Wang Lin, Xu JiPing, Liu Jing, Ma XianChun, Sun WenBing. Anesthetic management strategies for patients with cirrhotic portal hypertension[J]. Journal of Clinical Hepatology, 2018, 34(1): 188-191. doi: 10.3969/j.issn.1001-5256.2018.01.041
[8]	Niu XiaoWei, Liu TongTing, Wei Zhi. Advances in the effect of carvedilol in prevention and treatment of esophageal variceal bleeding in patients with cirrhosis[J]. Journal of Clinical Hepatology, 2018, 34(1): 184-187. doi: 10.3969/j.issn.1001-5256.2018.01.040
[9]	Han Dan, Qi XingShun, Yu Yang, Zhu Qiang, Guo XiaoZhong. An excerpt of portal hypertensive bleeding in cirrhosis: risk stratification, diagnosis and management - 2016 practice guidance by the American Association for the Study of Liver Diseases[J]. Journal of Clinical Hepatology, 2017, 33(3): 422-427. doi: 10.3969/j.issn.1001-5256.2017.03.004
[10]	Nie Wei, Lin Wei, Liang Shan, Fan ZuoPeng, Chou LiXia, Liu YiRong, Ma LiXia, Wei XinHuan, Hu ZhongJie, Zhang Jing. Clinical features of cirrhotic patients with different degrees of portal vein thrombosis and their clinical significance[J]. Journal of Clinical Hepatology, 2017, 33(3): 472-475. doi: 10.3969/j.issn.1001-5256.2017.03.015
[12]	Ding Qian, Li Zhen, Liu Bin, Ling LiPing, Zhang ChunQing. Inhibitory effect of carvedilol on human hepatic stellate cell activation and fibrosis induced by platelet-derived growth factor-BB and related mechanisms of action[J]. Journal of Clinical Hepatology, 2017, 33(3): 485-491. doi: 10.3969/j.issn.1001-5256.2017.03.018
[13]	Zhai YaNan, Li Lei, Yin Liang, Guo QiHong, Lei JunQiang, Guo ShunLin, Zhang ChunYu, Wang HaiJun, Wen XiaoXiao. Role of dual-source CT low-dose whole liver perfusion imaging in evaluating liver blood perfusion after transjugular intrahepatic portosystemic shunt in cirrhotic patients with portal hypertension[J]. Journal of Clinical Hepatology, 2016, 32(10): 1894-1899. doi: 10.3969/j.issn.1001-5256.2016.10.014
[14]	Bao HanKang, Wei XiuLi. Clinical effects of hand-assisted laparoscopic vs open splenectomy combined with pericardial devascularization the treatment of portal hypertension in liver cirrhosis[J]. Journal of Clinical Hepatology, 2015, 31(3): 431-433. doi: 10.3969/j.issn.1001-5256.2015.03.027
[15]	Lu XiaoMin, Wang ZhenNing, Yang Jun. Significance of molecular markers of prethrombotic state in monitoring portal vein thrombosis in patients with liver cirrhosis[J]. Journal of Clinical Hepatology, 2015, 31(3): 404-406. doi: 10.3969/j.issn.1001-5256.2015.03.022
[16]	Yang ChunJiao, Qi XingShun, Guo XiaoZhong. Research advances in role of carvedilol in management of cirrhotic portal hypertension: a review of clinical trials[J]. Journal of Clinical Hepatology, 2015, 31(3): 469-471. doi: 10.3969/j.issn.1001-5256.2015.03.038
[17]	Duan LiWei, Sun Han, Chen YongSheng, Tian YueLi, Li DongFu. Hemodynamic effects of partial splenic artery embolization in patients with liver cirrhosis and portal hypertension[J]. Journal of Clinical Hepatology, 2013, 29(2): 142-145.
[18]	Shang JianZhong, Ma LongFei, Ma HongWei, Zhao QiuFang, Zhao LinHua, Li XiaoFei, Fan YanFeng, Zhang SuE. Effect of autologous bone marrow- derived mesenchymal stem cells on portal hemodynamics in patients with liver cirrhosis[J]. Journal of Clinical Hepatology, 2013, 29(11): 848-851. doi: 10.3969/j.issn.1001-5256.2013.10.012

Supplements(0)

Cited By

Cited by

Periodical cited type(2)

1.	鞠迪，李汨，韩曼，房冰莹，闫曙光，安荣，李京涛. 益脾养肝方对肝癌前病变大鼠肝星状细胞活化的影响. 陕西中医药大学学报. 2024(02): 83-88 .
2.	黄玉，苟雪源，关茜，焦俊喆，闫曙光，常占杰，闫瑞娟，李京涛. 基于M1型巨噬细胞极化-慢性炎症-肝细胞恶变探究益脾养肝方治疗肝癌前病变作用机制. 中国中医药信息杂志. 2024(10): 81-88 .

Other cited types(0)

Proportional views

Proportional views

通讯作者: 陈斌, bchen63@163.com

1.
沈阳化工大学材料科学与工程学院沈阳 110142

Tables(3)

Get Citation

PDF

XML

Article Metrics

Article views (541) PDF downloads(29)

Features of liver function in pediatric patients infected with Delta variant versus Omicron variant of severe acute respiratory syndrome coronavirus 2

DOI: 10.3969/j.issn.1001-5256.2022.09.023